Drove delivery and support of diverse product portfolio to improve business efficiencies and probability of success for discovery research programs spanning target identification and validation through commit-to-candidate selection.* Formulated value proposition for transcriptomics-enabled Connectivity Map capability and delivered technical solution projected to return $50M+ over 5 years through reduced lead discovery cycle time and cost avoidances.* Reduced time to locate and order chemical building blocks from several hours to less than 10 minutes through design, development, delivery, and integration of custom software within the corporate digital chemistry platform (LiveDesign).* Enabled insights from data by fostering collaboration between scientific SMEs and computational scientists through delivery of several products including an omics data visualizer, a human genetics data ingestion tracker and an associated analysis browser.* Streamlined quarterly tech investment decisions by defining business value streams and OKRs and coupling those with value propositions associated with user persona-specific problem statements.* Clarified quarterly technology investment decisions by clearly defining business value streams and OKRs and aligning these with value propositions tied to user persona-specific problem statements.* Sustained momentum of the advanced analytics team through the first half of 2021 as interim director, by providing guidance on portfolio direction, product management principles and personal development.

Partnered with Research leaders, SMEs, and data engineers to accelerate time to insight and power more highly informed project progression decisions through the design and delivery of “BIOME” data products (from disparate sources including molecular properties, bioassay protocol, and experimental results).* Slashed annual costs by $750K by eliminating computational scientists' effort on lower-value data wrangling activities. Delivered additional cost savings by retiring 10’s of bespoke data marts.*Improved medicine design SAR capabilities by providing expanded assay results to downstream enterprise analytics tools (e.g., LiveDesign platform, serving 100s of medicinal and computational chemists).* Transformed biopharma predictive design processes by providing and more effectively integrating antibody property and experimental result information into downstream analytics tools (e.g., Spotfire-driven dashboards), lauded by VP of Discovery: "In terms of building future capabilities, this may well be the most important achievement in the biopharma discovery space this year.

Functioned as business analysis team lead and strategic tech partner for R&D screening and compound profiling platform team of 400 personnel supporting hit identification, lead identification, and lead optimization.* Delivered $8.5M in defined business benefits by designing and implementing $2M tech portfolio strategy to support paradigm shift towards phenotypic-driven drug discovery.* Following acquisition of BMS HIV Discovery, mitigated risks of IP loss and data availability by coordinating across 3 companies (GSK, BMS, and ViiV) to map common processes and agree plans for tech systems transition.* Improved PMO tech refresh delivery efficiency 3-fold by piloting and refining "fast track" project management framework, leading to department-wide adoption and rollout.

Primary relationship manager to R&D screening & compound profiling platform team of 400 personnel that support Hit ID, Lead ID and Lead Optimization. Improved bioassay screening process performance while ensuring operational stability through optimal use of Tech assets and resources.

Primary relationship manager to Infectious Diseases, Metabolic Pathways and Cardiovascular Therapeutic Discovery units with 150 personnel. Elicited and vetted business needs to improve Lead ID and Optimization process performance while ensuring operational stability through optimal use of Tech assets and resources.

Advanced the use of biological and chemical data as a strategic asset, enabling efficient flow of information within and across R&D decision processes.

Proactively liaised across R&D, Tech, and Informatics stakeholders to ensure consistent collection, integration, and use of enterprise-ready bioassay data.